Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

18 Jan 2025

Abstract excerpt

Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response against refractory/relapsed neuroblastoma so far. We investigated how oncogenic MYCN levels influence tumor cell response to CAR T cells, as one possible factor limiting clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39828101
DOI: 10.1016/j.phrs.2025.107608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacyPMID 39828101Read ↗

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN -Not-Amplified Human NeuroblastomaSemantic proximity Read ↗

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in NeuroblastomaSemantic proximity Read ↗

The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapiesSemantic proximity Read ↗

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaSemantic proximity Read ↗

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET DatabaseSemantic proximity Read ↗

Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastomaSemantic proximity Read ↗

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastomaSemantic proximity Read ↗

Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor CellsSemantic proximity Read ↗

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.Semantic proximity Read ↗

Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in NeuroblastomaSemantic proximity Read ↗

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formationSemantic proximity Read ↗

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.